SINTX Technologies to Participate in Sidoti & Company Investor Conference
Rhea-AI Summary
SINTX Technologies (NASDAQ: SINT) will present at Sidoti & Company’s Year End Virtual Investor Conference held December 10–11, 2025. Management's presentation is scheduled for Wednesday, December 10, 2025 at 3:15 P.M. ET. A live webcast is available and one-on-one meetings can be scheduled by emailing Sintx@kcsa.com. To join the company's email distribution list, email Sintx@kcsa.com with SINT in the subject line.
Positive
- None.
Negative
- None.
Key Figures
Market Reality Check
Peers on Argus 1 Down
SINT gained 5.77% while key medical device peers like XAIR (-11.54%) and CODX (-6.14%) were down, indicating stock-specific strength rather than a sector-wide move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 01 | Supply agreement | Positive | -21.2% | Evonik deal to manufacture silicon nitride–PEEK compound at commercial scale. |
| Nov 13 | Earnings & business update | Neutral | -10.8% | Q3 2025 update with FDA clearance, new revenues, and capital raises. |
| Nov 03 | Product launch | Positive | +4.7% | Launch of OsseoSculpt biologic with first commercial revenue recorded. |
| Oct 20 | FDA clearance | Positive | -15.4% | FDA 510(k) clearance for SINAPTIC Foot & Ankle Osteotomy Wedge System. |
| Oct 16 | Patent allowance | Positive | -5.3% | USPTO Notice of Allowance expanding antipathogenic materials IP coverage. |
Recent history shows frequent selloffs on seemingly positive developments, with only one of the last five news events aligning positively with price reaction.
Over the past few months, SINTX reported multiple positive operational milestones, including FDA 510(k) clearance for the SINAPTIC Foot & Ankle system, a new biologic launch (OsseoSculpt), and an AI-focused supply agreement with Evonik. It also expanded IP protection in antipathogenic materials. Despite these steps, four of the last five news items saw negative 24-hour price reactions, suggesting a pattern where good news often met with selling pressure. Today’s conference participation fits into this ongoing communication cadence.
Regulatory & Risk Context
An effective S-3 resale registration dated Oct 23, 2025 covers up to 1,741,539 shares of common stock for selling stockholders. The company is not selling shares in this prospectus and would only receive up to $8.3 million if related warrants, with exercise prices around $4.31–$4.79, are exercised for cash. Any proceeds are designated for working capital and general corporate purposes.
Market Pulse Summary
This announcement highlights SINTX’s participation in a Sidoti virtual investor conference on December 10–11, 2025, providing a forum to update investors on recent FDA clearances, product launches, and IP expansion. Historically, the stock’s reactions to news have often been volatile, with several positive items followed by short-term declines. Investors may monitor how management frames growth plans, capital structure, and the existing resale registration allowing up to $8.3M in potential warrant-exercise proceeds.
AI-generated analysis. Not financial advice.
SALT LAKE CITY, Utah, Dec. 08, 2025 (GLOBE NEWSWIRE) -- SINTX Technologies, Inc. (NASDAQ: SINT) (“SINTX” or the “Company”), today announced that management will be presenting at Sidoti & Company’s Year End Virtual Investor Conference, held December 10-11, 2025.
Sidoti's Year End Virtual Investor Conference
Dates: December 10-11, 2025
Presentation Date and Time: Wednesday, December 10, 2025 at 3:15 P.M. ET
Webcast: https://sidoti.zoom.us/webinar/register/WN_O_OnAvXpQki63dk_9JbUYw
To schedule a one-on-one meeting with SINTX Technologies’ management team, please email KCSA Strategic Communications at Sintx@kcsa.com.
To be added to the Sintx Technologies email distribution list, please email Sintx@kcsa.com with SINT in the subject line.
About SINTX Technologies, Inc.
Headquartered in Salt Lake City, Utah, SINTX Technologies, Inc. (NASDAQ: SINT) is an advanced ceramics company that develops, manufactures, and commercializes silicon nitride biomaterials, composites, devices, and related technologies for medical and other high-value applications.
SINTX Contacts:
Jack Perkins or Maria Hocut
KCSA Strategic Communications
Sintx@kcsa.com
SINTX Technologies, Inc.
801.839.3502
IR@sintx.com
FAQ
When will SINTX Technologies (NASDAQ: SINT) present at the Sidoti Year End Virtual Investor Conference?
How can investors watch the SINTX Technologies (SINT) webcast from the Sidoti conference?
How do I schedule a one-on-one meeting with SINTX Technologies management at the Sidoti conference?
How can I join SINTX Technologies' (SINT) investor email distribution list?
What are the dates of Sidoti & Company's Year End Virtual Investor Conference where SINTX will appear?
Is the SINTX presentation at Sidoti & Company available to the public via webcast?
